NP
NPCE
NeuroPace Inc
$16.27
+2.65%
$540.4M
No data for this timeframe.
Vol
Market Cap$540.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$80.7M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 1S
Insider Net $-$399.3K
SEC Reports2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001528287·Prev Close $15.85
Recent Activity
May 15, 2026
Insider
Becker Joel sold 45,880 shares
CHIEF EXECUTIVE OFFICER @ $0.00 ($0.00)
May 15, 2026
Insider
Becker Joel sold 122,190 shares
CHIEF EXECUTIVE OFFICER @ $0.00 ($0.00)
May 15, 2026
Insider
Williams Patrick F. sold 44,800 shares
Chief Financial Officer @ $0.00 ($0.00)
May 12, 2026
SEC
NeuroPace reported Q1 2026 non-GAAP revenue (excluding DIXI) of $22.0M, up 20.1% YoY, and raised full-year 2026 revenue
8-K — Impact 7/10
Apr 21, 2026
SEC
NeuroPace Inc has filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting, which includes voti
DEFA14A — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
222,300 shares ($3.4M)
Inst.
BANK OF AMERICA CORP — DOUBLED
170,439 shares ($2.6M)
May 12, 2026
earnings_calendar
NPCE Q1 2026 Earnings Scheduled — 2026-05-12
Price Targets
$20.00
+22.9% upside
Strong Buy
Current $16.27
Low $18.00
Median $20.00
High $22.00
8 analysts
$18.00
$22.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 16, 2025 | UBS | MAINTAIN | Buy → Buy |
| Dec 10, 2025 | JP Morgan | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 | $-0.26 — $-0.16 | 24% YoY | 7 |
| Next Q | $-0.10 ▲ +7.5% | $-0.16 — $-0.03 | 6% YoY | 7 |
| Current FY | $-0.56 ▲ +6.7% | $-0.73 — $-0.36 | 15% YoY | 7 |
| Next FY | $-0.30 ▲ +15.9% | $-0.68 — $0.10 | 47% YoY | 7 |
Latest Reports
BULLISH
8-K
7/10
NeuroPace reported Q1 2026 non-GAAP revenue (excluding DIXI) of $22.0M, up 20.1% YoY, and raised full-year 2026 revenue
May 12, 2026
NEUTRAL
DEFA14A
3/10
NeuroPace Inc has filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting, which includes voti
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $39.3M | — |
| VANGUARD GROUP INC | $22.9M | — |
| FMR LLC | $9.6M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $3.4M | ADD |
| BANK OF AMERICA CORP | $2.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | Becker Joel | A | $0.00 |
| May 15, 2026 | Becker Joel | A | $0.00 |
| May 15, 2026 | Williams Patrick | A | $0.00 |
| May 15, 2026 | Williams Patrick | A | $0.00 |
| May 15, 2026 | Morrell Martha | A | $0.00 |
8 institutional holders with $80.7M total value (5,225,031 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, FMR. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 2,547,784 | $39.3M | 48.8% | — |
| 2 | VANGUARD GROUP INC | 1,482,228 | $22.9M | 28.4% | — |
| 3 | FMR LLC | 624,947 | $9.6M | 12.0% | DOUBLED +150.3% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 222,300 | $3.4M | 4.3% | ADD +72.2% |
| 5 | BANK OF AMERICA CORP /DE/ | 170,439 | $2.6M | 3.3% | DOUBLED +195.5% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 76,153 | $1.2M | 1.5% | ADD +75.5% |
| 7 | TWO SIGMA INVESTMENTS, LP | 68,092 | $1.1M | 1.3% | DOUBLED +252.9% |
| 8 | WELLS FARGO & COMPANY/MN | 33,088 | $510.9K | 0.6% | ADD +65.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 129,100 | 222,300 | +72.2% | $3.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 57,677 | 170,439 | +195.5% | $2.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 19,293 | 68,092 | +252.9% | $1.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 20,010 | 33,088 | +65.4% | $510.9K | 2025-Q4 |
| UBS Group AG | DOUBLED | 27,034 | 65,237 | +141.3% | $672.6K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 15,865 | 20,010 | +26.1% | $206.3K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 88,638 | 19,293 | -78.2% | $198.9K | 2025-Q3 |
| FMR LLC | DOUBLED | 249,905 | 625,446 | +150.3% | $7.0M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 32,432 | 88,638 | +173.3% | $987.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 39,237 | 68,849 | +75.5% | $767.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 131,175 | 46,553 | -64.5% | $518.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 25,350 | 15,865 | -37.4% | $176.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 86,300 | 155,800 | +80.5% | $1.9M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 40,407 | 125,446 | +210.5% | $1.5M | 2025-Q1 |
| UBS Group AG | DOUBLED | 6,910 | 26,044 | +276.9% | $320.1K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 6,483 | 25,350 | +291.0% | $311.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 17,881 | 40,407 | +126.0% | $452.2K | 2024-Q4 |
| UBS Group AG | ADD | 4,085 | 6,910 | +69.2% | $77.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 4,204 | 6,483 | +54.2% | $72.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 36,537 | — | $254.7K | 2024-Q3 |
7 unique insiders with 1 transactions. Net insider value: -$399.3K ($0.00 bought, $399.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Becker Joel | CHIEF EXECUTIVE OFFICER | A | 45,880 | $0.00 | $0.00 |
| May 15, 2026 | Becker Joel | CHIEF EXECUTIVE OFFICER | A | 122,190 | $0.00 | $0.00 |
| May 15, 2026 | Williams Patrick F. | Chief Financial Officer | A | 44,800 | $0.00 | $0.00 |
| May 15, 2026 | Williams Patrick F. | Chief Financial Officer | A | 16,820 | $0.00 | $0.00 |
| May 15, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | A | 14,550 | $0.00 | $0.00 |
| May 15, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | A | 5,460 | $0.00 | $0.00 |
| Mar 24, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | F | 1,341 | $13.27 | $17.8K |
| Mar 20, 2026 | Geiger Uri | Director | A | 913 | $13.00 | $11.9K |
| Mar 20, 2026 | LACOB JOSEPH | Director | A | 865 | $13.00 | $11.2K |
| Mar 20, 2026 | Kumar Rakhi | Director | A | 1,153 | $13.00 | $15.0K |
| Mar 20, 2026 | Fischer Frank M | Director | A | 1,826 | $13.00 | $23.7K |
| Mar 3, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | F | 1,340 | $13.83 | $18.5K |
| Mar 3, 2026 | Becker Joel | CHIEF EXECUTIVE OFFICER | F | 5,023 | $13.83 | $69.5K |
| Feb 27, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | F | 358 | $14.58 | $5.2K |
| Feb 27, 2026 | Becker Joel | CHIEF EXECUTIVE OFFICER | F | 1,126 | $14.58 | $16.4K |
| Feb 20, 2026 | Morrell Martha | CHIEF MEDICAL OFFICER | F | 3,412 | $14.34 | $48.9K |
| Dec 15, 2025 | Morrell Martha | CHIEF MEDICAL OFFICER | SELL | 25,000 | $15.97 | $399.3K |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.00 mean target
+22.9% upside
Strong Buy (1.13)
$18.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $16.27 |
| Target Low | $18.00 |
| Target Mean | $20.00 |
| Target Median | $20.00 |
| Target High | $22.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.26 | $-0.16 | 24.5% | -0.1% | 2↑ 0↓ | $0.0B | -3.9% | 7 |
| Next Q 2026-09-30 |
$-0.10 | $-0.16 | $-0.03 | 6.5% | +7.5% | 0↑ 1↓ | $0.0B | -0.8% | 7 |
| Current FY 2026-12-31 |
$-0.56 | $-0.73 | $-0.36 | 15.1% | +6.7% | 2↑ 1↓ | $0.1B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-0.30 | $-0.68 | $0.10 | 46.9% | +15.9% | 2↑ 0↓ | $0.1B | 23.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.196 | |
| 7d ago | $-0.199 | +0.003 |
| 30d ago | $-0.196 | -0.000 |
| 60d ago | $-0.196 | -0.000 |
| 90d ago | $-0.199 | +0.002 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | UBS | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
NPCE Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
NPCE Q1 2026 Earnings Scheduled — 2026-05-07
Mar 3, 2026
earnings_calendar
NPCE Q4 2025 Earnings After Market Close — 2026-03-03